| Literature DB >> 21342495 |
Lian-Hua Cui1, Min-Ho Shin, Hee Nam Kim, Hye-Rim Song, Jin-Mei Piao, Sun-Seog Kweon, Jin-Su Choi, Woo-Jun Yun, Young-Chul Kim, In-Jae Oh, Kyu-Sik Kim.
Abstract
BACKGROUND: This study was designed to investigate an association between methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and the risk of lung cancer in a Korean population.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21342495 PMCID: PMC3048494 DOI: 10.1186/1471-2350-12-28
Source DB: PubMed Journal: BMC Med Genet ISSN: 1471-2350 Impact factor: 2.103
General characteristics of subjects
| Characteristics | Cases n (%) | Controls n (%) |
|---|---|---|
| 3938 | 1700 | |
| 64.8 ± 9.6 | 52.2 ± 14.3 | |
| ≤65 years | 1803 (45.8) | 1308 (76.9) |
| > 65 years | 2135 (54.2) | 392 (23.1) |
| Male | 3128 (79.4) | 821 (48.3) |
| Female | 810 (20.6) | 879 (51.7) |
| Never | 900 (22.8) | 1000 (58.8) |
| Ever | 2951 (74.9) | 655 (38.5) |
| unknown | 87 (2.2) | 45 (2.6) |
| ADC | 1523 (38.7) | |
| SQC | 1519 (38.6) | |
| SCLC | 574 (14.6) | |
| Others | 322 (8.2) |
SD, standard deviation; ADC, adenocarcinoma; SQC, squamous cell carcinoma;
SCLC, small cell lung cancer; others, large cell carcinoma and mixed types; *, p < 0.01.
Distribution of MTHFR C677T and their association with lung cancer risk
| MTHFR C677T | Lung cancer n (%) | Control n (%) | ORa | 95% CI |
|---|---|---|---|---|
| 1361 (34.5) | 540 (31.8) | 1 | ||
| 1909 (48.5) | 862 (50.7) | 0.90 | 0.77-1.04 | |
| 668 (17.0) | 298 (17.5) | 0.88 | 0.71-1.07 | |
| 2577 (65.4) | 1160 (68.2) | 0.89 | 0.78-1.03 |
aAdjusted for age, gender; OR, odds ratio; CI, confidence interval.
Subgroup analysis for the MTHFR C677T polymorphisms
| CT vs. CC | TT vs. CC | CT+TT vs. CC | ||||||
|---|---|---|---|---|---|---|---|---|
| ORa | 95%CI | ORa | 95%CI | ORa | 95%CI | |||
| 0.90 | 0.96 | |||||||
| Male | 0.89 | 0.74-1.08 | 0.90 | 0.63-1.16 | 0.89 | 0.74-1.07 | ||
| Female | 0.91 | 0.72-1.16 | 0.85 | 0.63-1.16 | 0.90 | 0.72-1.12 | ||
| 0.39 | 0.84 | |||||||
| | 0.96 | 0.80-1.16 | 0.87 | 0.68-1.12 | 0.94 | 0.79-1.12 | ||
| > 65 | 0.80 | 0.62-1.04 | 0.90 | 0.64-1.25 | 0.83 | 0.65-1.05 | ||
| 0.55 | 0.77 | |||||||
| Never | 0.90 | 0.72-1.12 | 0.80 | 0.60-1.07 | 0.87 | 0.71-1.08 | ||
| Ever | 0.89 | 0.73-1.10 | 0.97 | 0.73-1.28 | 0.91 | 0.75-1.11 | ||
| 0.64 | 0.99 | |||||||
| ADC | 0.89 | 0.75-1.05 | 0.93 | 0.74-1.16 | 0.90 | 0.76-1.06 | ||
| SQC | 0.78 | 0.64-0.96 | 0.80 | 0.61-1.04 | 0.79 | 0.65-0.95 | ||
| SCLC | 0.96 | 0.75-1.22 | 0.83 | 0.59-1.15 | 0.92 | 0.73-1.17 | ||
| Others | 0.93 | 0.70-1.26 | 0.77 | 0.51-1.15 | 0.89 | 0.67-1.18 | ||
SCLC, small cell lung cancer; SQC, squamous cell carcinoma; ADC, adenocarcinoma; others, large cell carcinoma and mixed types.
ORa: odds ratio adjusted for age and gender, CI, confidence interval;
Pb: p values for heterogeneity.